Dr. Raquel Amaro Silva
SURGEON PONTEVEDRA
Collegiate No. 362607457
Graduated in Medicine and Surgery from the University of Santiago de Compostela with a Master's Degree in Aesthetic Medicine and Trichology and Hair Micrograft. She currently works as a doctor and hair surgeon in Hospital Capilar as head of the headquarters Hospital Capilar Pontevedra.
research in treatments for alopecia has been a hot topic in recent months thanks to Breezulaa topical drug based on clascoterone which could become a new alternative for treating androgenetic alopecia.
Although it's presented as a promising option, it's important to understand what this treatment can and cannot actually do. Like other drugs such as dutasteride and finasterideIts main objective is to slow the progression of alopecianot to recover hair that has already been lost.
Furthermore, there are already existing infiltrated treatments that act directly on the hair follicle and offer comparable efficacy with a similar or even lower side effect profileTherefore, they remain a widely used option in clinical practice.
Breezula is the trade name for clascoterone, a compound being investigated as a topical treatment for androgenetic alopecia.
This is a 5% hair lotion that is applied directly to the scalp. Its purpose is to act locally on the hair follicle to block the action of the hormones responsible for hair miniaturization.
Currently, the drug is in phase 3 of clinical trials, the last step before its possible approval for commercial use.
Androgenetic alopecia is caused by a combination of hormonal and genetic factors. The hormone DHT (dihydrotestosterone) plays a role in this process, causing the progressive miniaturization of the hair follicle.
Over time, the following occurs:
When this happens, hair loss is irreversible. Therefore, all treatments for alopecia share a common goal: to halt or slow down this process. Clascoterone acts as an androgen receptor blocker. In other words, it prevents DHT from binding to the hair follicle and continuing the miniaturization process. When applied topically, its action is primarily local to the scalp.
Currently, there are various treatments for androgenetic alopecia, each with different mechanisms of action and methods of administration. One of the most interesting aspects of Breezula, and the reason it has generated so much interest, is that it is a topical solution that acts locally and directly on the androgen receptor of the hair follicle. In contrast, there are classic medications, such as Finasteride or Dutasteride, which act in the same way, but because they are absorbed into the bloodstream, they can cause side effects, although in a small percentage of patients.
| Feature | Finasteride / Dutasteride | Mesotherapy with drugs | Breezula (Clascoterona) |
|---|---|---|---|
| Route of administration | Oral | Topical, through direct microinjections into the follicle | Topical, through a lotion applied to the scalp |
| Type of treatment | Systemic drug for daily use | Infiltrated medical treatment | Topical drug for daily application |
| Frequency | Once a day | Spaced sessions (every 3–4 months) | 1 or 2 times a day (according to protocol) |
| Mechanism of action | They inhibit the enzyme 5 alpha reductasereducing the conversion of testosterone into DHT, hormone responsible for follicular miniaturization | They inhibit the enzyme 5 alpha reductasereducing the conversion of testosterone into DHT, hormone responsible for follicular miniaturization | It inhibits the action of the androgens in the hair folliclereducing the effect of the DHT in a localized manner |
| Advantages | Highly effective in slowing hair loss and stabilizing alopecia | Direct action on the hair follicle | Localized action on the scalp |
| Limitations | It may cause side effects in a small percentage of patients; it requires continued use. | It requires several sessions and periodic maintenance. | Currently in phase 3 clinical trials and not yet commercially available |
The phase 3 SCALP-1 and SCALP-2 studies have evaluated the efficacy of Breezula in more than 1.400 patients with androgenetic alopecia.
During the study:
The results showed improvements in hair density compared to placebo and a favorable safety profile.
However, it is important to emphasize that these figures reflect relative improvements compared to the placebo group, which in alopecia refers to progressive hair loss. Therefore, it does not mean that patients have increased the number of hairs by 500%, but rather that the treatment showed better results compared to the group that did not receive treatment for alopecia.
Breezula could be an interesting option for different types of patients. Among them:
One of the most important points that patients should know is that no current medical treatment can recover a follicle that has already died.
When the miniaturization process has progressed too far:
In these cases, the only way to recover lost hair is through a FUE hair transplant.
Medical treatments—including Breezula, finasteride, dutasteride, or infiltrated treatments—have a different goal: to slow hair loss, stabilize alopecia, and protect existing hair.
After completing phase 3 clinical trials, the treatment is currently in a 12-month safety follow-up phase.
If the regulatory process continues as planned, Breezula could reach the market between the end of 2026 and 2027.
Breezula represents an interesting line of research within the treatments for alopecia, especially due to its topical approach.
However, it is important to remember that:
Meanwhile in Hospital Capilar We offer infiltrated treatments and effective medical therapies that can stop alopecia and improve hair density.
Request your free assessment now at Hospital Capilar And discover how we can help you stop hair loss today, with the technology and experience that support us.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit elit, luctus nec ullamcorper mattis, dapibus leo pulvinar.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit elit, luctus nec ullamcorper mattis, dapibus leo pulvinar.